A Study Evaluating the Safety and Efficacy of EDIT-301 in Participants With Severe Sickle Cell Disease (RUBY)
Condition(s):Sickle Cell Disease; HemoglobinopathiesLast Updated:February 1, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Sickle Cell Disease; HemoglobinopathiesLast Updated:February 1, 2024Recruiting
Condition(s):Sickle Cell DiseaseLast Updated:November 8, 2023Recruiting
Condition(s):Sickle Cell DiseaseLast Updated:January 17, 2024Recruiting
Condition(s):Genetic Disease; GenomicsLast Updated:March 21, 2024Recruiting
Condition(s):Sickle Cell DiseaseLast Updated:September 23, 2019Not yet recruiting
Condition(s):Sickle Cell Disease; NephropathyLast Updated:March 7, 2024Not yet recruiting
Condition(s):Sickle Cell Disease; Vaso-occlusive Crisis; Vaso-occlusive Pain Episode in Sickle Cell DiseaseLast Updated:March 15, 2024Recruiting
Condition(s):Sickle Cell DiseaseLast Updated:November 30, 2022Recruiting
Condition(s):Sickle Cell Disease; Vaso-occlusive CrisisLast Updated:February 13, 2024Recruiting
Condition(s):Sickle Cell Anemia; Beta-thalassemia Major; Diamond-blackfan AnemiaLast Updated:August 4, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.